FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2915548778> ?p ?o ?g. }

• W2915548778 endingPage "51" @default.
• W2915548778 startingPage "51" @default.
• W2915548778 abstract "Abstract Introduction. Myeloproliferative neoplasm (MPNs) are clonal stem cell disorders characterized by increased production of mature blood cells. Ph-negative MPNs (Ph- MPNs) encompass polycythemia vera (PV), essential thrombocythemia (ET), primary myelofibrosis (PMF) and chronic neutrophilic leukemia (CNL), amongst others. The discovery of Jak2 kinase activating mutations in MPNs provided a rationale for the targeting of Jak2 by small molecule kinase inhibitor. Interestingly, MPNs induced by MPL (MPLW515L) or Calreticulin (CALRfs-frame-shift mutations) were also found to be dependent on JAK2 signaling. Thus, provided a rationale for JAK2 targeting in this group of MPNs. However, unlike imatinib (BCR-ABL inhibitor) treatment in chronic myeloid leukemia (CML), ruxolitinib (Jak2 inhibitor) treatment does not eliminate the mutant clone. Besides, inhibition or genetic deletion of Jak2 kinases causes substantial hematologic toxicity that includes moderate to severe thrombocytopenia and anemia as well as non-hematological adverse events, including neurological toxicity. The latter led to the discontinuation of clinical development of several JAK2 inhibitors. Furthermore, mouse knock-out studies suggest that prolonged inhibition of Jak2 will be detrimental for normal hematopoietic and adult tissue homeostasis. These observations warrant identifying additional therapeutic targets that must be safe and able to eliminate the mutant clone. Any therapy with the stated goal to successfully treat and possibly eradicate mutant cells and eventually cure must show differential toxicity toward tumor cells relative to normal cells. In this regard, CML represents a valuable paradigm to understand the mechanisms driving therapeutic response to TKI treatment. The cytotoxic response and clonal selectivity of BCR-ABL inhibitor are due to the dependence of leukemic cells on driver oncogene (BCR-ABL) kinase, where acute inhibition of BCR-ABL by imatinib results in oncogenic shock causing cell death. A recent study demonstrated that the AP1 transcription factor c-Fos and dual specificity phosphatase, Dusp1, mediate dependence to oncogenic kinase signaling. Perhaps more interestingly, these studies provided evidence that expression levels of c-Fos and Dusp1 regulate apoptotic thresh-hold in cancer cells such that lower levels confer sensitivity, while higher levels drive resistance to drug treatments. Thus, these two genes not only crucial for oncogenic transformation but also regulate the therapeutic efficacy of kinase inhibitors (Kesarwani M, et. al. Nature Medicine, 2017). Results. We reasoned that MPN induced by activated Jak2 signaling, similar to LSCs in CML, might have elevated expression of c-Fos and Dusp1 resulting to a higher apoptotic threshold, and thus, abrogating the cytotoxic effect of Jak2 inhibitors. As envisioned, a gene expression analysis of c-Fos and Dusp1 revealed higher expression of Dusp1 (4-10 fold in comparison to normal cells), but not the c-fos, in both mouse (induced by expression of Jak2V617F, MplW515L, and Calrfs in mouse bonemarrow cells) and human primary MPN patient samples (data not presented). Interestingly, mice transplanted with Jak2V617F expressing bonemarrow cells show dependence on Dusp1. Genetic deletion of Dusp1 is synthetic lethal to Jak2V617F expressing hematopoietic cells (Fig. 1). Mice transplanted with Jak2V617F expressing cells lacking Dusp1 show gradual depletion and completely cleared from the bonemarrow within five weeks of post-transplantation (Fig. 1E). In contrast, mice transplanted with cells expressing pMSCV-Ires-GFP (vector) and MPLW515L show stable engraftment. These data provide evidence that Jak2V617F is uniquely addicted to Dusp1 and crucial for Jak2V617F mediate pathogenesis. Therefore, targeting of Dusp1 may exert curative response in Jak2 mutated MPNs, which constitute ~90% MPN cases. Conclusion. We show that both mouse and human MPNs have higher Dusp1 expression irrespective of MPN drivers (JAK2, MPL, and CALR). Jak2V617F is uniquely addicted to the Dusp1 expression, where genetic deletion of Dusp1 is lethal to Jak2V617F expressing cells, but not to the other MPN drivers, such as, MPLW515L. Thus, providing a rationale for targeting the Dusp1 in Jak2 mutated MPNs to eliminate the mutant clones and cure the disease. Disclosures No relevant conflicts of interest to declare." @default.
• W2915548778 created "2019-03-02" @default.
• W2915548778 creator A5018387768 @default.
• W2915548778 creator A5041698482 @default.
• W2915548778 creator A5049906793 @default.
• W2915548778 creator A5087476037 @default.
• W2915548778 date "2018-11-29" @default.
• W2915548778 modified "2023-09-28" @default.
• W2915548778 title "Loss of DUSP1 Is Synthetic Lethal to JAK2V617F" @default.
• W2915548778 doi "https://doi.org/10.1182/blood-2018-99-115503" @default.
• W2915548778 hasPublicationYear "2018" @default.
• W2915548778 type Work @default.
• W2915548778 sameAs 2915548778 @default.
• W2915548778 citedByCount "0" @default.
• W2915548778 crossrefType "journal-article" @default.
• W2915548778 hasAuthorship W2915548778A5018387768 @default.
• W2915548778 hasAuthorship W2915548778A5041698482 @default.
• W2915548778 hasAuthorship W2915548778A5049906793 @default.
• W2915548778 hasAuthorship W2915548778A5087476037 @default.
• W2915548778 hasConcept C109159458 @default.
• W2915548778 hasConcept C158617107 @default.
• W2915548778 hasConcept C203014093 @default.
• W2915548778 hasConcept C2776112149 @default.
• W2915548778 hasConcept C2777583451 @default.
• W2915548778 hasConcept C2778729363 @default.
• W2915548778 hasConcept C2778837598 @default.
• W2915548778 hasConcept C2779788118 @default.
• W2915548778 hasConcept C2780007613 @default.
• W2915548778 hasConcept C2780076729 @default.
• W2915548778 hasConcept C2781057849 @default.
• W2915548778 hasConcept C2781107747 @default.
• W2915548778 hasConcept C28328180 @default.
• W2915548778 hasConcept C3019892230 @default.
• W2915548778 hasConcept C47450691 @default.
• W2915548778 hasConcept C502942594 @default.
• W2915548778 hasConcept C71924100 @default.
• W2915548778 hasConcept C86803240 @default.
• W2915548778 hasConcept C89560881 @default.
• W2915548778 hasConcept C95444343 @default.
• W2915548778 hasConceptScore W2915548778C109159458 @default.
• W2915548778 hasConceptScore W2915548778C158617107 @default.
• W2915548778 hasConceptScore W2915548778C203014093 @default.
• W2915548778 hasConceptScore W2915548778C2776112149 @default.
• W2915548778 hasConceptScore W2915548778C2777583451 @default.
• W2915548778 hasConceptScore W2915548778C2778729363 @default.
• W2915548778 hasConceptScore W2915548778C2778837598 @default.
• W2915548778 hasConceptScore W2915548778C2779788118 @default.
• W2915548778 hasConceptScore W2915548778C2780007613 @default.
• W2915548778 hasConceptScore W2915548778C2780076729 @default.
• W2915548778 hasConceptScore W2915548778C2781057849 @default.
• W2915548778 hasConceptScore W2915548778C2781107747 @default.
• W2915548778 hasConceptScore W2915548778C28328180 @default.
• W2915548778 hasConceptScore W2915548778C3019892230 @default.
• W2915548778 hasConceptScore W2915548778C47450691 @default.
• W2915548778 hasConceptScore W2915548778C502942594 @default.
• W2915548778 hasConceptScore W2915548778C71924100 @default.
• W2915548778 hasConceptScore W2915548778C86803240 @default.
• W2915548778 hasConceptScore W2915548778C89560881 @default.
• W2915548778 hasConceptScore W2915548778C95444343 @default.
• W2915548778 hasIssue "Supplement 1" @default.
• W2915548778 hasLocation W29155487781 @default.
• W2915548778 hasOpenAccess W2915548778 @default.
• W2915548778 hasPrimaryLocation W29155487781 @default.
• W2915548778 hasRelatedWork W1966797682 @default.
• W2915548778 hasRelatedWork W2388785926 @default.
• W2915548778 hasRelatedWork W2396715532 @default.
• W2915548778 hasRelatedWork W2414432918 @default.
• W2915548778 hasRelatedWork W2558450558 @default.
• W2915548778 hasRelatedWork W2706078606 @default.
• W2915548778 hasRelatedWork W2748837638 @default.
• W2915548778 hasRelatedWork W2915548778 @default.
• W2915548778 hasRelatedWork W3134409041 @default.
• W2915548778 hasRelatedWork W3208584668 @default.
• W2915548778 hasVolume "132" @default.
• W2915548778 isParatext "false" @default.
• W2915548778 isRetracted "false" @default.
• W2915548778 magId "2915548778" @default.
• W2915548778 workType "article" @default.